US 11364240
Pyruvate kinase activators for use in treating blood disorders
granted A61KA61K31/5025A61K31/506
Quick answer
US patent 11364240 (Pyruvate kinase activators for use in treating blood disorders) held by Agios Pharmaceuticals, Inc. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/5025, A61K31/506, A61K31/519, A61K45/06